Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants

Business Wire February 4, 2014

Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease

Business Wire January 22, 2014

Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases

Business Wire January 9, 2014

Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström's Macroglobulinemia

Business Wire December 4, 2013

Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

Business Wire November 25, 2013

Five Star Equities Issues New Research Reports on FONR, IDRA, JOSB and JWN

Accesswire November 18, 2013

Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update

Business Wire November 14, 2013

Five Star Equities Issues New Research Reports on BKS, IDRA, MOBI and QUIK

Accesswire October 7, 2013

InvestorsGuru.com 34 Filtered Mid-Day Market Movers Recap

Investors Guru October 5, 2013

Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants

Business Wire September 30, 2013

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Business Wire September 25, 2013

Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants

Business Wire September 24, 2013

Five Star Equities Issues New Research Reports on EZCH, IDRA, PSTI and UNFI

Accesswire September 13, 2013

Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference

Business Wire September 12, 2013

Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference

Business Wire September 10, 2013

Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas

Business Wire August 29, 2013

Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial

Business Wire July 18, 2013

Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors

Business Wire July 10, 2013

Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases

Business Wire July 1, 2013

Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013

Business Wire June 21, 2013